proteomic analyses
Recently Published Documents





Chunmei Liu ◽  
Qichao Wei ◽  
Xia Li ◽  
Dong Han ◽  
Jiqian Liu ◽  

2022 ◽  
Vol 229 ◽  
pp. 113057
Guihua Zhang ◽  
Zhenming Yu ◽  
Lingling Zhang ◽  
Bo Yao ◽  
Xianzhen Luo ◽  

2021 ◽  
pp. 2100172
Yiwu Yan ◽  
Bo Zhou ◽  
Yeon‐Joo Lee ◽  
Sungyong You ◽  
Michael R. Freeman ◽  

2021 ◽  
Vol 12 ◽  
Juan José Nieto-Fontarigo ◽  
Sofia Tillgren ◽  
Samuel Cerps ◽  
Asger Sverrild ◽  
Morten Hvidtfeldt ◽  

BackgroundBoth anti-viral and anti-inflammatory bronchial effects are warranted to treat viral infections in asthma. We sought to investigate if imiquimod, a TLR7 agonist, exhibits such dual actions in ex vivo cultured human bronchial epithelial cells (HBECs), targets for SARS-CoV-2 infectivity.ObjectiveTo investigate bronchial epithelial effects of imiquimod of potential importance for anti-viral treatment in asthmatic patients.MethodsEffects of imiquimod alone were examined in HBECs from healthy (N=4) and asthmatic (N=18) donors. Mimicking SARS-CoV-2 infection, HBECs were stimulated with poly(I:C), a dsRNA analogue, or SARS-CoV-2 spike-protein 1 (SP1; receptor binding) with and without imiquimod treatment. Expression of SARS-CoV-2 receptor (ACE2), pro-inflammatory and anti-viral cytokines were analyzed by RT-qPCR, multiplex ELISA, western blot, and Nanostring and proteomic analyses.ResultsImiquimod reduced ACE2 expression at baseline and after poly(I:C) stimulation. Imiquimod also reduced poly(I:C)-induced pro-inflammatory cytokines including IL-1β, IL-6, IL-8, and IL-33. Furthermore, imiquimod increased IFN-β expression, an effect potentiated in presence of poly(I:C) or SP1. Multiplex mRNA analysis verified enrichment in type-I IFN signaling concomitant with suppression of cytokine signaling pathways induced by imiquimod in presence of poly(I:C). Exploratory proteomic analyses revealed potentially protective effects of imiquimod on infections.ConclusionImiquimod triggers viral resistance mechanisms in HBECs by decreasing ACE2 and increasing IFN-β expression. Additionally, imiquimod improves viral infection tolerance by reducing viral stimulus-induced epithelial cytokines involved in severe COVID-19 infection. Our imiquimod data highlight feasibility of producing pluripotent drugs potentially suited for anti-viral treatment in asthmatic subjects.

2021 ◽  
pp. 131828
Yi Wang ◽  
Jinqiu Wang ◽  
Yaoqiang Shi ◽  
Haolong Ye ◽  
Wei Luo ◽  

Peptides ◽  
2021 ◽  
Vol 146 ◽  
pp. 170643
Wai Lok So ◽  
Thomas C.N. Leung ◽  
Wenyan Nong ◽  
William G. Bendena ◽  
Sai Ming Ngai ◽  

Sign in / Sign up

Export Citation Format

Share Document